ZBH
ZIMMER BIOMET HOLDINGS, INC.
NYSE · Healthcare · Medical - Devices · US
$95.53
+0.56%Year over year
Reported trailing growth
- Revenue
- +8.6%
- EBITDA
- +2.7%
- EBIT
- +6.2%
- EPS
- +0.2%
- Free cash flow
- +28.5%
- Operating cash flow
- +4.8%
Forward estimates
Based on analyst estimates
- Revenue
- +3.7%
- EBITDA
- +44.3%
- EPS
- +117.0%
Three-year CAGR
- Revenue
- +5.9%
- EBITDA
- +14.1%
- EBIT
- +25.1%
- Net income
- +45.0%
- EPS
- +47.9%
- Free cash flow
- +11.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026